ArticleJACC. Basic to translational science2026
Unmasking Hormonal Mechanisms of Hypertension in Obesity.
Article in JACC. Basic to translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors.Circulation research · 2026Review
- Cardiometabolic regulation by adipocyte-derived leptin and the brain melanocortin system.Clinical science (London, England : 1979) · 2026Review
- Primary aldosteronism.Nature reviews. Disease primers · 2026Review
- Is Obesity a Major Driver of Primary Aldosteronism?JACC. Basic to translational science · 2026Article
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
Understanding hormonal mechanisms of obesity-related hypertension may inform targeted therapy. Participants with obesity and hypertension underwent deep-phenotyping procedures to detect the primary aldosteronism phenotype, low-renin phenotype, renin-dependent aldosteronism phenotype, and ACTH-independent hypercortisolism. In total, 51.9% of participants had a primary aldosteronism phenotype, of which approximately one-half also had superimposed renin-dependent aldosteronism. Another 23.4% of participants had only renin-dependent aldosteronism that was characterized by higher aldosterone levels and kaliuresis, and 9.2% of participants also had hypercortisolism. Over 80% of individuals with obesity-related hypertension exhibited overlapping pathologic phenotypes of aldosteronism and/or hypercortisolism, providing mechanistic evidence to support the efficacy of aldosterone- and cortisol-directed therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.